Press Release RSS Feed (opens in new window)
Press release year list 2023 2022 2021 2020 2019 2018 2017 2016
12/20/2018
Tetra Successfully Completes Phase 1 Study With Vaporized Version of PPP001
12/11/2018
Tetra Bio-Pharma Confirms Agreements With Multiple Suppliers
12/06/2018
Tetra Bio-Pharma in Process of Filing Patent Application Exceeding its Data Protection Initial Assumption for its PPP001
12/04/2018
Tetra Bio-Pharma Responds to Shareholders
12/04/2018
Tetra Bio-Pharma Convenes First National Medical Advisory Board
12/03/2018
Tetra Natural Health Will Deliver 20 containers of Hemp Energy Drink to Meet Consumer Demand
11/30/2018
Tetra Bio-Pharma Closes Financing With Aphria Inc.
11/27/2018
Tetra Bio-Pharma Bolsters Intellectual Property Position and Product Pipeline
11/26/2018
Tetra Bio-Pharma’s Dr. Chamberland Goes to Washington!
Download PDF format download (opens in new window)
11/22/2018
Tetra Bio-Pharma Seeks Solutions for Second Hand Smoke From Cannabis
11/20/2018
Tetra Bio-Pharma Enters into Binding Proposal with Quantum Pharma Inc.
11/15/2018
Pilot Study to Investigate a Cannabinoid Derived Drug in Dogs
11/13/2018
Tetra Bio-Pharma Promotes Steeve Néron to Senior Vice President, Marketing & Medical Affairs
11/06/2018
Tetra Bio-Pharma Enters into Non-Binding Proposal to Acquire Panag Pharma Inc.
11/01/2018
Tetra Natural Health Signs Exclusive Agreement for the Distribution of their Hemp Energy Drink in Canada and the USA
11/01/2018
Tetra Bio-Pharma Obtains Health Canada Approval to Conduct a Phase 1 Pharmacokinetic & Safety Study Using Vaporized Version of PPP001
10/24/2018
Tetra Bio-Pharma Appoints Richard Giguère Chief Executive Officer of Tetra Natural Health
10/15/2018
Tetra Bio-Pharma Names Dr. Guy Chamberland as Chief Executive Officer and Chief Scientific Officer
10/11/2018
Tetra Bio-Pharma’s PPP002 on Track After Type C Meeting with FDA
10/03/2018
Tetra Bio-Pharma Moves PPP001 Closer to Commercial Manufacturing with the Issuance of a Drug Establishment License to Ford’s Pharmacy
09/27/2018
Tetra Bio-Pharma Announces PPP002 Program Update Following Type B Meeting with U.S. FDA
09/24/2018
Tetra Bio-Pharma Takes One Step Closer to the Commercialization of Cannabis Oil-Based Retail Products
09/20/2018
Tetra Bio-Pharma Announces Significant Progress on Storz & Bickel Co-Development in Treating Fibromyalgia
09/13/2018
Health Canada Reclassifies Tetra Bio-Pharma’s Inhalation Device Making it Eligible for Reimbursement
09/11/2018
Tetra Bio-Pharma Accelerates its European Drug Registration Activities
09/05/2018
Tetra Bio-Pharma Secures CBD Supply Agreement for Genacol Partnership
08/31/2018
Tetra Bio-Pharma Announces Record Date for Dividend-in-Kind of North Bud Farms Shares
08/30/2018
Tetra Bio-Pharma Adds New Marketing Vice-President
08/23/2018
Tetra Bio-Pharma Targets Rare Cancers in the United States
08/14/2018
Genacol Canada Corporation and Tetra Bio-Pharma Team Up to bring Innovative Cannabinoid Treatments to Self-Care Market in Canada
08/13/2018
Tetra Bio-Pharma Announces Initiation of Coverage by Paradigm Capital
08/09/2018
Health Canada Gives Green Light to Tetra Bio-Pharma’s Cannabis Vs. Fentanyl Trial
08/08/2018
Tetra Bio-Pharma’s Dr. Chamberland to Announce Health Canada’s Green Light for the Cannabis vs. Fentanyl Trial
08/03/2018
Tetra Bio-Pharma Provides Extension to North Bud Farms
07/26/2018
Tetra Bio-Pharma Confirms Meetings With FDA
07/19/2018
Tetra Natural Health Announces Upcoming Launch of Hemp Energy Drink
07/16/2018
Tetra Bio-Pharma Targets Multi-Billion Dollar Fibromyalgia Market
06/29/2018
Tetra Bio-Pharma’s Evidence-Based Business Model Confirmed
06/19/2018
Tetra Bio-Pharma Adds a New Leader for its Commercial Operations
06/18/2018
Tetra Bio-Pharma Takes on Fentanyl in Head to Head Trial for the Treatment of Breakthrough Pain
06/13/2018
Tetra Bio-Pharma Inc. Provides Corporate Update Ahead of Its Annual General Meeting
06/12/2018
Tetra Bio-Pharma Inc. Announces Changes Relating to the Nomination of its Directors
06/05/2018
Tetra Bio-Pharma Inc. Strengthens Senior Management Team
05/17/2018
Tetra Natural Health Signs a Supply Agreement with Namaste Technologies for the Marketing and Distribution of Rx Princeps™, its Premium Medicinal Cannabis Product
05/17/2018
Tetra Bio-Pharma Inc. Clarifies AGM Meeting Location
05/09/2018
Dr. Guy Chamberland is interviewed by Everett Jolly on Tetra-Biopharma Drug Development Plan
05/04/2018
Tetra BioPharma Signs Second Commercialization Deal with Azevedos Industria Farmaceutica, S.A. for the Lead RX product PPP001
04/24/2018
Tetra Bio-Pharma Signs Landmark Commercialization Term Sheet for its Lead Pharmaceutical Product, PPP001, in Israel
04/12/2018
Tetra Bio-Pharma Clinical Study on Cannabis Oil Capsules for Patients Suffering from Chronic Pain should be completed by Fall 2018
04/10/2018
Tetra Bio-Pharma Announces the appointment of Gregory Drohan to its board of directors
04/04/2018
Tetra Bio-Pharma Initiates Enrolment of Patients in Phase 3 PPP001 Smokable Cannabis Pellet Study
04/03/2018
Tetra Bio-Pharma Names Guy Chamberland as Interim CEO
03/27/2018
Tetra Bio-Pharma Inc. Announces the Closing of $4,292,000 Non-Brokered Private Placement
03/20/2018
Tetra Bio-Pharma Added to Leading Cannabis ETF: Horizons Marijuana Life Sciences Index
03/19/2018
Tetra Bio-Pharma Completes Acquisition of Remaining 20% Interest in PhytoPain Pharma Inc.
03/16/2018
Tetra Bio-Pharma Inc. Announces a Non-Brokered Private Placement
03/14/2018
Tetra Bio-Pharma Announces FDA Orphan Drug Designation for PPP001 in Treatment of Complex Regional Pain Syndrome
03/08/2018
Tetra Bio-Pharma Signs Co-development and Distribution Partnership Term Sheet
03/06/2018
Tetra Bio-Pharma Takes First Steps into European Medical Cannabis Market
03/05/2018
Tetra Bio-Pharma Announces Closing of Bought Deal Financing
02/26/2018
Tetra Bio-Pharma names Aphria CFO as Chairman of Audit Committee
02/22/2018
Tetra Bio-Pharma Announces the Completion of GrowPros Transaction
02/12/2018
Neptune et Tetra Bio-Pharma concluent une entente de codéveloppement de produits antidouleurs et anti-inflammatoires à base d’huiles de cannabinoïdes purifiés
02/12/2018
Neptune and Tetra Bio-Pharma Enter Co-Development Agreement for Purified Cannabinoid Oil-Based Products targeting Pain and Inflammation
02/08/2018
Tetra Bio-Pharma Announces Upsizing of Previously Announced Offering
02/08/2018
Tetra Bio-Pharma Announces $8 million Bought Deal Offering
02/05/2018
Tetra Bio-Pharma reçoit l'approbation de Santé Canada pour la phase 3 d’essai clinique pour un médicament de prescription de cannabis séché inhalable
02/04/2018
Tetra Bio-Pharma Receives Health Canada Phase 3 Clinical Trial Approval For Smokable Dried Cannabis Prescription Drug
01/29/2018
Tetra Bio-Pharma Receives Health Canada Approval for Phase 2 Cannabis Oil Trial in Partnership with Sante Cannabis
01/16/2018
Tetra Bio-Pharma Receives Approval from Health Canada of its Phase 1 Clinical Trial with PPP005 (Cannabis Oil)
01/02/2018
Tetra Bio-Pharma Enters into Agreement to Acquire Remaining 20% Interest in Phytopain Pharma Subsidiary